Healthpoint Biotherapeutics – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "Healthpoint Biotherapeutics - Product Pipeline Review - 2012" provides data on the Healthpoint Biotherapeutics's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Healthpoint Biotherapeutics's corporate website, SEC filings, investor presentations and featured press releases, both from Healthpoint Biotherapeutics and industry-specific third party sources, put together by our team.
Scope
- Healthpoint Biotherapeutics - Brief Healthpoint Biotherapeutics overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Healthpoint Biotherapeutics human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Healthpoint Biotherapeutics with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Healthpoint Biotherapeutics's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Healthpoint Biotherapeutics's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Healthpoint Biotherapeutics in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Healthpoint Biotherapeutics's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Healthpoint Biotherapeutics.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Healthpoint Biotherapeutics and identify potential opportunities in those areas.
Table of Contents
Table of Contents
List of Tables
List of Figures
Healthpoint Biotherapeutics Snapshot
Healthpoint Biotherapeutics Overview
Key Information
Key Facts
Healthpoint Biotherapeutics – Research and Development Overview
Key Therapeutic Areas
Healthpoint Biotherapeutics – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Healthpoint Biotherapeutics – Pipeline Products Glance
Healthpoint Biotherapeutics – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Healthpoint Biotherapeutics Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Healthpoint Biotherapeutics – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Healthpoint Biotherapeutics – Drug Profiles
Drug For Diabetic Foot Ulcer
Product Description
Mechanism of Action
R&D Progress
HP802-247
Product Description
Mechanism of Action
R&D Progress
ICX-SKN
Product Description
Mechanism of Action
R&D Progress
Healthpoint Biotherapeutics – Pipeline Analysis
Healthpoint Biotherapeutics – Pipeline Products by Therapeutic Class
Healthpoint Biotherapeutics – Pipeline Products by Route of Administration
Healthpoint Biotherapeutics – Recent Pipeline Updates
Healthpoint Biotherapeutics - Dormant Projects
Healthpoint Biotherapeutics - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Cyzact
Healthpoint Biotherapeutics – Company Statement
Healthpoint Biotherapeutics – Locations And Subsidiaries
Head Office
Healthpoint Biotherapeutics, Recent Developments
Healthpoint Biotherapeutics- Press Release
Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet
Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers
Jun 16, 2009: Healthpoint-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study for HP802-247
Feb 20, 2009: Phase III Results Of Intercytex's Cyzact Fail To Meet Primary Endpoint
Financial Deals Landscape
Healthpoint Biotherapeutics, Deals Summary
Healthpoint Biotherapeutics, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Healthpoint Biotherapeutics Acquires Regranex Gel From Systagenix
Healthpoint Acquires Two Cell Based Technologies From Intercytex
Healthpoint Acquires Collagenase Topical Business From BioSpecifics Technologies
Partnerships
Healthpoint Enters Into Agreement With Hydrofera
Licensing Agreements
CareFusion Enters Into Licensing Agreement With Healthpoint
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Healthpoint Biotherapeutics, Key Information
Healthpoint Biotherapeutics, Key Facts
Healthpoint Biotherapeutics – Pipeline by Indication, 2012
Healthpoint Biotherapeutics – Pipeline by Stage of Development, 2012
Healthpoint Biotherapeutics – Monotherapy Products in Pipeline, 2012
Healthpoint Biotherapeutics – Phase III, 2012
Healthpoint Biotherapeutics – Phase I, 2012
Healthpoint Biotherapeutics – Pre-Clinical, 2012
Healthpoint Biotherapeutics – Pipeline By Therapeutic Class, 2012
Healthpoint Biotherapeutics – Pipeline By Route of Administration, 2012
Healthpoint Biotherapeutics – Recent Pipeline Updates, 2012
Healthpoint Biotherapeutics - Dormant Developmental Projects,2012
Healthpoint Biotherapeutics - Discontinued Pipeline Products, 2012
Healthpoint Biotherapeutics, Deals Summary
Healthpoint Biotherapeutics Acquires Regranex Gel From Systagenix
Healthpoint Acquires Two Cell Based Technologies From Intercytex
Healthpoint Acquires Collagenase Topical Business From BioSpecifics Technologies
Healthpoint Enters Into Agreement With Hydrofera
CareFusion Enters Into Licensing Agreement With Healthpoint
List of Figures
Healthpoint Biotherapeutics – Pipeline by Indication, 2012
Healthpoint Biotherapeutics – Pipeline by Stage of Development, 2012
Healthpoint Biotherapeutics – Monotherapy Products in Pipeline, 2012
Healthpoint Biotherapeutics – Pipeline By Therapeutic Class, 2012 16